MedTrace Logo

Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors

NCT07512583 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 178

Last updated 2026-06-08

No results posted yet for this study

Summary

This is a multicenter, open-label, multi-cohort phase Ib/II clinical study to evaluate the efficacy and safety of TQB2930 in combination with TQB2102 in patients with HER2-expressing advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

TQB2930 injection+TQB2102 for injection

TQB2930 Injection is a Human Epidermal Growth Factor Receptor 2 (HER2) bispecific antibody. TQB2102 for injection is a HER2 - targeted dual epitope Antibody-Drug Conjugate (ADC).

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-27
Primary Completion
2028-03-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07512583 on ClinicalTrials.gov